Characterizing second line and beyond therapies for primary central nervous system lymphomas

Abstract Primary central nervous system (CNS) lymphoma (PCNSL) is a rare and aggressive lymphoma that affects the CNS without other systemic involvement. High‐dose methotrexate (HDMTX)‐based regimens are recommended frontline treatment, followed by consolidation with either high‐dose chemotherapy, whole brain radiation (WBRT) +/− sequential temozolomide (TMZ), or autologous stem cell transplant (autoSCT). Despite advancements with HDMTX and rituximab, up to half of patients will relapse. Treatment for relapsed or refractory (R/R) disease varies widely as preferred regimens are not well‐established. Our study aimed to provide real‐world characterization of R/R PCNSL therapies. The secondary objective was characterization of consolidation methods after frontline treatment. This retrospective, descriptive analysis included 54 adult PCNSL patients that received a HDMTX‐based frontline regimen between 4/1/2016 and 7/1/2022. Patients receiving HDMTX for the purpose of secondary CNS lymphoma, non‐B cell origin PCNSL, and intraocular lymphoma were excluded. Thirty‐one patients (57%) received consolidation therapy with rituximab and high‐dose cytarabine (R‐HDAC), WBRT, or both. Thirteen patients (24%) proceeded with autoSCT. Twenty‐five patients had disease progression, with 17 patients receiving second line treatment. The second line treatments were WBRT (24%), clinical trial (18%), rituximab with lenalidomide (R 2 ; 18%), re‐induction with HDMTX‐based regimens (18%), ibrutinib with rituximab (12%) and R‐HDAC (12%). Seven patients progressed, and all received third line treatment. Treatments varied, including R 2 ; ibrutinib +/− HDMTX; rituximab, methotrexate, and cytarabine; R‐HDAC; R‐nivolumab; and WBRT. Five patients received a fourth line regimen of R +/− lenalidomide, R‐HDMTX, or nivolumab monotherapy. Regimens used for the three patients who received fifth line treatment and beyond included R‐TMZ and pembrolizumab monotherapy in addition to previously described regimens. Regimen selection is varied and highly dependent on physician preference and patient factors, including clinical trial eligibility, prior therapies, performance status, organ function, and treatment intent. Prospective clinical trials are needed to guide optimal management.